Business Context and Reporting Period
This Form 8-K is filed by AgeX Therapeutics, Inc. (trading symbol: AGE) for the reporting period of February 15, 2023. The company is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California. The filing discloses a new debt obligation and the issuance of unregistered equity securities.
Key Financial Metrics and Transactions
- Debt Obligation: AgeX drew $1,000,000 under an Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited.
- Credit Facility: The amended note allows for up to an additional $2,000,000 in borrowings until May 9, 2023, subject to lender discretion and a $1,000,000 cap per draw.
- Repayment Terms: The outstanding principal balance is due on February 14, 2024.
- Equity Issuance: In connection with the draw, AgeX issued warrants to purchase 801,924 shares of common stock.
- Warrant Terms: Exercise price is $0.6235 per share, based on the closing price on February 10, 2023.
- Collateral: Obligations are secured by a security interest in AgeX assets granted under a February 14, 2022 Security Agreement.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or total liquidity positions outside of this specific transaction.
Material Changes
The primary material change is the increase in debt and potential equity dilution resulting from the $1,000,000 draw on February 15, 2023. This transaction amends a prior note dated February 14, 2022, extending the borrowing capacity and maintaining existing terms regarding conversion rights and origination fees.
Outlook, Risks, and Contingencies
- Forward-Looking Statements: The company includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors.
- Conversion Risk: The note includes provisions allowing the lender to convert the loan balance and accrued fees into shares of AgeX common stock.
- Liquidity Contingency: Future draws up to $2,000,000 are subject to Juvenescence's discretion to approve each loan.
Investor Verification Checklist
- Verify the total outstanding principal balance of the Amended Note and any accrued fees as of the filing date.
- Review the full text of the Security Agreement to understand the specific assets pledged as collateral.
- Confirm the exact terms regarding the conversion of debt to equity and the impact on existing shareholder dilution.
- Assess the company's current cash runway relative to the new debt obligation and the May 9, 2023 maturity of the credit facility.